Gene Editing of Embryos Gives Insight Into Basic Human Biology
By Marissa Fessenden,
Smithsonian.com [cites CGS' Marcy Darnovsky]
| 09. 21. 2017
A genetic tool allows researchers to disable a gene key to human development in a closely regulated experiment
For the first time, scientists edited a gene in fertilized human eggs critical to early development. The experiments helped the researchers learn about fundamental human biology in a way they could not through research on mice.
Researchers led by Kathy Niakan, a developmental biologist at the Francis Crick Institute in London, disabled a gene that codes for a protein called OCT4, known to be active in stem cells that can develop into all the cell types found in the body, reports Gretchen Vogel for Science. Turning the gene off ensured that cells from fertilized human eggs failed to form placental cells, yolk sac cells or even cells that would typically become a fetus.
Disabling the same gene in mouse embryos gives different results: Those embryos became balls of mostly placental cells. The findings suggest that the gene controls the fate of several cell lineages and plays a slightly different role in humans than in mice.
"This is opening up the possibility...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...